Gilead’s Kite announces real-world safety, effectiveness of Yescarta

Kite, a Gilead (GILD) Company, announced real-world data evaluating the safety and effectiveness of Yescarta for patients with relapsed/refractory large B-cell lymphoma assigned to treatment in an outpatient setting versus those assigned to an inpatient setting in a hospital. The analysis, based on data collected from the Center for International Blood and Marrow Transplant Research, CIBMTR, registry, observed that safety and effectiveness outcomes for people treated as outpatients were comparable to those patients who received treatment in a hospital. The results were shared in a presentation during the 2025 American Society of Clinical Oncology, ASCO, Annual Meeting. Data were collected from the CIBMTR observational database. The final analysis assessed data on patients with R/R LBCL from 75 treatment centers, comparing 119 individuals who were assigned to receive Yescarta in the outpatient setting to 119 patients assigned to receive Yescarta in the inpatient setting. With a median follow-up of 12 months, no general differences were found between the 2 groups in the rates of cytokine release syndrome, neurologic events or immune effector cell-associated neurotoxicity syndrome grade greater than or equal to 3.